The General Hospital Corporation

Millennium Pharmaceuticals Limited

Massachusetts General Hospital Corporation

Cyril H Benes

Peter G Smith

Jeffrey E Settleman

George J Mulligan

Stephen J Blakemore

Eric S Lightcap

Matthew C Schu

Jonathan L Blank

Wilhelm Haas

The disclosure features methods of identifying specific drug candidates for disease treatment, the methods including: for pairs of associated expressed proteins in a protein-protein interaction network for a plurality of biological samples, comparing relative concentration values of the associated proteins in each of the biological samples to identify outliers among a distribution of the relative concentration values, identifying a set of proteins involved in dysregulated protein-protein interactions in the network based on the outliers, and predicting an efficacy of one or more drug candidates from among a set of drug candidates for treating a disease based on the identified set of proteins and information about one or more of proteins, protein complexes, biological pathways, and functional modules targeted by the set of drug candidates.

Multiplexed proteomics and predictive drug candidate assessment

Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

Biomarkers of response to NAE inhibitors

Growing community of inventors

Brookline, MA, United States of America

Cyril H Benes